B.Riley Financial analyst Mayank Mamtani reiterated a Buy rating on TG Therapeutics (NASDAQ:TGTX) on Friday, setting a price target of $52, which is approximately 71.17% above the present share price of $30.38.
Mamtani expects TG Therapeutics to post earnings per share (EPS) of -$0.47 for the fourth quarter of 2020.
The current consensus among 6 TipRanks analysts is for a Strong Buy rating of shares in TG Therapeutics, with an average price target of $41.5.
The analysts price targets range from a high of $52 to a low of $30.
In its latest earnings report, released on 06/30/2020, the company reported a quarterly revenue of $38 thousand and a net profit of -$50.85 million. The company's market cap is $3.85 billion.
According to TipRanks.com, B.Riley Financial analyst Mayank Mamtani is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 20.7% and a 51.68% success rate.
TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY.